Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma

WEDNESDAY, Oct. 16, 2024-- For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields longer progression-free survival (PFS) than brentuximab vedotin with doxorubicin, vinblastine...